Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

ABBOTT LABORATORIES Aktie

 >ABT Aktienkurs 
96.32 EUR    -0.2%    (TradegateBSX)
Ask: 96.38 EUR / 70 Stück
Bid: 95.96 EUR / 70 Stück
Tagesumsatz: 1073 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ABT Aktie über LYNX handeln
>ABT Performance
1 Woche: +3,8%
1 Monat: +23,2%
3 Monate: +33,3%
6 Monate: +1,6%
1 Jahr: -13,2%
laufendes Jahr: -9,0%
>ABBOTT LABORATORIES Aktie
Name:  ABBOTT LABORATORIES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US0028241000 / 850103
Symbol/ Ticker:  ABL (Frankfurt) / ABT (NYSE)
Kürzel:  FRA:ABL, ETR:ABL, ABL:GR, NYSE:ABT
Index:  S&P500
Profil:  Abbott Laboratories is a global healthcare company that develops and markets a broad portfolio of medical devices, diagnostics, nutritional products, and branded generic medicines. Its current business is organized around four core segments: Medical ..
>Volltext..
Marktkapitalisierung:  166390.92 Mio. EUR
Unternehmenswert:  190520.92 Mio. EUR
Umsatz:  40265.53 Mio. EUR
EBITDA:  9599.42 Mio. EUR
Nettogewinn:  4671.79 Mio. EUR
Gewinn je Aktie:  2.68 EUR
Schulden:  28184.57 Mio. EUR
Liquide Mittel:  4411.62 Mio. EUR
Operativer Cashflow:  8561.34 Mio. EUR
Bargeldquote:  0.31
Umsatzwachstum:  11.46%
Gewinnwachstum:  -59.99%
Dividende je Aktie:  2.13 EUR
Dividendenrendite:  2.23%
Dividendenschätzung:  2.26%
Div. Historie:  15.07.26 - 0.550431€
15.04.26 - 0.53442895€
>weitere anzeigen...
Insiderhandel 1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 555.347 Euro.
Suchwörter:  ABBOTT LABORATORIES, ABBOTT LABS, ABBOTT LAB, (ABT), ABT
Letzte Datenerhebung:  16.08.26
>ABT Kennzahlen
Aktien/ Unternehmen:
Aktien: 1730.38 Mio. St.
Frei handelbar: 99.31%
Rückkaufquote: 0.85%
Mitarbeiter: 115000
Umsatz/Mitarb.: 0.33 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 8.31%
Bewertung:
KGV: 35.45
KGV lG: 20.07
KUV: 4.1
KBV: 3.71
PEG-Ratio: -
EV/EBITDA: 19.85
Rentabilität:
Bruttomarge: 52.81%
Gewinnmarge: 11.6%
Operative Marge: 16.44%
Managementeffizenz:
Gesamtkaprendite: 5.59%
Eigenkaprendite: 10.63%
 >ABT Anleihen 
>ABT Peer Group
Gesundheit, Nahrungsergänzungsmittel & Wellnessprodukte, Medizinprodukte & -technik/ Implantate/ Wundpflege, Stoffwechselerkrankungen (Diabetes/ Adipositas), Herz-Kreislauf- Behandlung/ Kardiologie
 
14.08.26 - 05:01
Insiderhandel: EXECUTIVE VICE PRESIDENT verkauft Aktien von Abbott Laboratories im Wert von 642506 USD (Insiderkauf)
 
Morrone, Louis H. - Vorstand - Tag der Transaktion: 2026-08-11...
13.08.26 - 13:54
Here Are Thursday′s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More (24/7 Wall St.)
 
Pre-Market Stock Futures: Futures are trading higher, as traders and investors breathed a big sigh of relief on Wednesday after the consumer price index data came in right on Wall Street expectations, with a 3.4% year-over-year print and a 0.01% month-over-month increase. Core CPI, which excludes the volatile food and energy costs, rose 2.5%. After ... Here Are Thursday's Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More...
11.08.26 - 16:01
Google Health Kooperation beflügelt Abbott Laboratories Aktie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.08.26 - 18:15
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom? (Zacks)
 
Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution....
07.08.26 - 23:12
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet....
07.08.26 - 19:00
NVST vs. ABT: Which Stock Is the Better Value Option? (Zacks)
 
NVST vs. ABT: Which Stock Is the Better Value Option?...
07.08.26 - 18:15
Here′s How ABT Broadens Diagnostics Growth Base With Oncology Expansion (Zacks)
 
Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness....
03.08.26 - 18:51
Matrix Asset Advisors′ Large Cap Value Portfolio adds ABT and MCD; exits NSRGY (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 17:48
Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant (24/7 Wall St.)
 
Abbott Laboratories (NYSE:ABT) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside. Barclays analyst Matt Miksic carries the highest active target at $143, translating to about 35% in gains from here. Abbott is a diversified healthcare giant with a market cap near $182.9 billion, operating across ... Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant...
02.08.26 - 14:24
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors....
31.07.26 - 22:00
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? (Fool)
 
Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement....
29.07.26 - 01:00
These 3 Companies Reported Record Results and Raised Guidance (Zacks)
 
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks....
28.07.26 - 19:03
What′s next for Abbott Laboratories after its earnings surprise? (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.07.26 - 16:45
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends (Zacks)
 
ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch....
27.07.26 - 16:15
Is Abbott Stock Attractive After Its Earnings and Guidance Update? (Zacks)
 
ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?...
27.07.26 - 13:00
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson (Zacks)
 
GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results....
24.07.26 - 05:21
PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records (PR Newswire)
 
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breachthat led to unauthorized access to the sensitive information of patients affiliated with Abbott Laboratories ("Abbott"), an Illinois-based healthcare and medical device company, and......
23.07.26 - 22:00
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now? (Zacks)
 
ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth....
21.07.26 - 17:06
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories (24/7 Wall St.)
 
JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?...
21.07.26 - 15:06
21st Century Healthcare Appoints Katie Doyle to Board of Directors (Business Wire)
 
TEMPE, Ariz.--(BUSINESS WIRE)--21st Century Healthcare, Inc. ("21st Century" or the "Company"), a leading manufacturer of vitamins, minerals, and supplements, and a portfolio company of Grant Avenue Capital LLC ("Grant Avenue"), a healthcare-focused, middle-market private equity firm, today announced the appointment of Katie Doyle to its Board of Directors. Ms. Doyle brings over 30 years of experience leading and advising consumer health and wellness companies. She most recently served as Executive Chair of FoodScience Corporation, a manufacturer of nutritional supplements with branded, private label, and co-manufacturing lines of business. Prior to FoodScience, Ms. Doyle was Chief Executive Officer of Swanson Health, a private equity-backed e-commerce health and wellness business, and Senior Vice President and Corporate Officer at Abbott Laboratories, where she led the Abbott Nutrition Products Division responsible for a $3.2 billion portfolio of consumer health brands. Ms. ...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer erwartet, daß in der Welt die Teufel mit Hörnern und die Narren mit Schellen einhergehen, wird stets ihre Beute oder ihr Spiel sein. - Arthur Schopenhauer
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!